Sugi Predict

Sugi Predict / Compounds / SCHEMBL15440424

SCHEMBL15440424

SCHEMBL15440424

COC(=O)c1cc(B2OC(C)(C)C(C)(C)O2)cc([N+](=O)[O-])c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ POLB P06746 2/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ PDGFRB P09619 1/20 0.41
▸ FGFR1 P11362 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ FLT1 P17948 1/20 0.41
▸ FGFR3 P22607 1/20 0.41
▸ KDR P35968 1/20 0.41
▸ VCAM1 P19320 1/20 0.38
▸ SIRT6 Q8N6T7 1/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ LMNA P02545 4/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20444546 0.89 ALDH1A1 (0.44) KMT2AMEN1POLBL3MBTL1ALDH1A1
SCHEMBL1857160 0.88 ALDH1A1 (0.44) KMT2AMEN1POLBL3MBTL1PDGFRB
SCHEMBL2770411 0.85 SIRT6 (0.47) KMT2AMEN1POLBL3MBTL1PDGFRB
SCHEMBL22655952 0.85 VCAM1 (0.40) KMT2AMEN1PDGFRBFGFR1PDGFRA
SCHEMBL1842087 0.81 DGAT1 (0.35) KMT2AMEN1PDGFRBKDRALDH1A1
SCHEMBL27433795 0.80 ROCK1 (0.37) PDGFRBKDRMAPTHIF1A
SCHEMBL5628047 0.79 KMT2A (0.56) KMT2AMEN1POLBL3MBTL1PDGFRB
SCHEMBL21200449 0.77 CFTR (0.39) KMT2AMEN1MAPTTSHRCACNA1F
SCHEMBL29867167 0.77 ALDH1A1 (0.39) KMT2AMEN1POLBL3MBTL1ALDH1A1
SCHEMBL27087930 0.77 ALDH1A1 (0.39) KMT2AMEN1POLBL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387402-A1 POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF EVOPOINT BIOSCIENCES CO LTD (CN) 2025-12-25 — — US disclosed
US-12390472-B2 Polysubstituted benzene compound and preparation method and use thereof Evopoint Biosciences Co., Ltd. (CN) 2025-08-19 — — US disclosed
CN-113480525-B Polysubstituted benzene ring compound, preparation method and application thereof 苏州信诺维医药科技股份有限公司 2024-02-27 — — CN disclosed
CN-113480525-A Polysubstituted benzene ring compound, preparation method and application thereof 苏州信诺维医药科技股份有限公司 2021-10-08 — — CN disclosed
US-20210308141-A1 POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF Evopoint Biosciences Co., Ltd. (CN) 2021-10-07 — — US disclosed
CN-111683936-B Polysubstituted benzene ring compound, preparation method and application thereof 苏州信诺维医药科技股份有限公司 2021-08-20 — — CN disclosed
EP-3831822-A1 POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) 2021-06-09 — — EP disclosed
CN-111683936-A Polysubstituted benzene ring compound, preparation method and application thereof 苏州信诺维医药科技有限公司 2020-09-18 — — CN disclosed
EP-2877462-B1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORP (US) 2019-09-04 — — EP disclosed
US-9133161-B2 Processes for preparing isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2015-09-15 — — US disclosed
US-9133161-B2 Processes for preparing isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2015-09-15 — — US disclosed
US-9133161-B2 Processes for preparing isoindoline-1,3-dione compounds CELGENE CORPORATION (US) 2015-09-15 — — US disclosed
EP-2877462-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS Celgene Corporation (US) 2015-06-03 — — EP disclosed
WO-2014018866-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — WO disclosed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — US disclosed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — US disclosed
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS CELGENE CORPORATION (US) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210308141-A1 POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF EZH2, BMI1, SUZ12 KMT2A 32/4885MEN1 2615/4885POLB 1642/4885
US-20140031552-A1 PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS UGT1A1, CYP3A5, CYP3A7 KMT2A 3731/4885MEN1 1452/4885POLB 487/4885
US-20250387402-A1 POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF EZH2, BMI1, DOT1L KMT2A 40/4885MEN1 2887/4885POLB 2918/4885
US-12390472-B2 Polysubstituted benzene compound and preparation method and use thereof EZH2, BMI1, SUZ12 KMT2A 32/4885MEN1 2615/4885POLB 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.